Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Pharma Labor Group Makes Direct Plea to Lawmakers against Off-Year Price Cuts
A group of pharma labor unions held an emergency gathering at a Diet building on April 2, leaning on dozens of legislators both from ruling and opposition parties to scrap “off-year” drug price revisions. Speaking to 41 Diet members, a…
To read the full story
Related Article
- Pharma Labor Group Renews Call for Abolition of Off-year Revisions
October 9, 2024
- Labor Union Group Urges Abolishment of Off-Year Price Revisions
June 27, 2024
- Japan Health Minister Hints Positive Stance on Off-Year Price Revisions
April 3, 2024
- Japan Needs New Rule to Price Drugs on Par with US, Europe: JPMA Director
October 27, 2023
ORGANIZATION
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
- JPMA Chief Seeks Concrete Reforms to Reward Innovation after Honebuto
July 31, 2026
- Patient Groups Launch Consortium to Improve Access to Drug Information
July 31, 2026
- Radiopharma Group Seeks Faster NHI Coverage for PET Imaging Agents
July 28, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…